DuPont Reports Fourth Quarter 2020 Results
- 4Q20 GAAP EPS from continuing operations of $0.37; adjusted EPS of $0.95
- 4Q20 Net Sales of $5.3 billion, up 1 percent; organic sales flat with the year-ago period
- 4Q20 GAAP Income from continuing operations of $279 million and Operating EBITDA of $1.3 billion
- ~$130 million in non-manufacturing costs savings in the quarter; delivered structural cost take-out target of ~$280 million for the year
- Operating cash flow of $1.3 billion; $1.0 billion free cash flow in the quarter increased 400% from 4Q19
News provided by
Share this article
DuPont (NYSE: DD) today announced financial results for the fourth quarter 2020. The leading positions we hold in automotive, protective garments, residential construction, semiconductor, and smartphones markets enabled us to capitalize on positive momentum and deliver strong fourth quarter results with sequential volume improvement in all segments, said Ed Breen, DuPont Executive Chairman
Share this article
Share this article
THOUSAND OAKS, Calif., Jan. 28, 2021 /PRNewswire/ Amgen (NASDAQ: AMGN) today announced results from the Phase 2 cohort of the CodeBreaK 100 clinical study evaluating investigational sotorasib (AMG 510) in 126 patients with
KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC). The results will be presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 2020 World Conference on Lung Cancer (WCLC) and are the first from a completed pivotal Phase 2 study in NSCLC with a median follow-up of more than one year.
Sotorasib demonstrated a confirmed objective response rate (ORR) and disease control rate (DCR) of 37.1% and 80.6%, respectively, and a median duration of response of 10 months (data cutoff of Dec.1, 2020; median follow-up time was 12.2 months). The results also highlighted that sotorasib is the first KRAS
Amgen Announces Webcast Of 2020 Fourth Quarter And Full Year Financial Results
News provided by
Share this article
Share this article
THOUSAND OAKS, Calif., Jan. 28, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, Feb. 2, 2021, after the close of the U.S. financial markets. The announcement will be followed by a conference call with the investment community at 5 p.m. EST. Participating in the call from Amgen will be Robert A. Bradway, chairman and chief executive officer, and other members of Amgen s senior management team.
Live audio of the conference call will be simultaneously broadcast over the internet and will be available to members of the news media, investors and the general public.
DuPont Exchange Offer to Expire January 29, 2021
Announces Preliminary Fourth Quarter and Full Year 2020 Total Company and N&B Segment Results
News provided by
Share this article
Share this article
WILMINGTON, Del., Jan. 26, 2021 /PRNewswire/ On December 31, 2020, DuPont (NYSE:DD) commenced its exchange offer (the Exchange Offer )
1 whereby DuPont stockholders can elect to tender shares of DuPont common stock in exchange for shares of Nutrition & Biosciences, Inc. ( N&B ) common stock. Any shares of N&B common stock remaining as a result of the participation level in the Exchange Offer, will be distributed to DuPont stockholders in a cleanup spin off. These transactions
DuPont : Exchange Offer to Expire January 29, 2021 marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.